Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 13:10:92.
doi: 10.3389/fphar.2019.00092. eCollection 2019.

Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results

Yuqin Huang  1 , Quan Zhou  1   2 , Wenguo Wang  1 , Qiang Huang  1 , Juan Liao  1 , Junyi Li  3 , Lei Long  1 , Tao Ju  1 , Quan Zhang  1 , Hanqin Wang  4 , Huaqiang Xu  1 , Mingli Tu  2   5
Affiliations

Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results

Yuqin Huang et al. Front Pharmacol. .

Abstract

Objective: To evaluate therapeutic efficacy of different combined antimicrobial treatments against Acinetobacter baumannii ventilator-associated pneumonia (VAP). Methods: Clinical outcomes were retrospectively analyzed to elucidate the efficacy of four combined antimicrobial regimens. The chessboard and micro broth dilution methods determined the minimum inhibitory concentrations (MICs) of four antiseptic drugs singly used and combined two drugs against 36 isolates of multidrug-resistant (MDR) A. baumannii. Results: The incidence of VAP was approximately 6.9% (237/3424) between January 1, 2015 and December 31, and 35.9% (85/237) of the cases were caused by A. baumannii. Among these cases, 60 belonged to AB-VAP, for whom antimicrobial treatment plan was centralized and clinical data was complete. Moreover, all 60 strains of A. baumannii were MDR bacteria from reports microbiological laboratory. Resistance rate was lowest for amikacin (68.3%) and ampicillin sulbactam (71.7%). Resistance rate for imipenem increased from 63.2 to 90.9% during the 3 years. However, in these 60 cases of AB-VAP, the combination between 4 antibiotics was effective in most cases: the effective rate was 75% (18/24) for sulbactam combined with etilmicin, 71.4% (10/14) for sulbactam combined with levofloxacin, 72.7% (8/11) for meropenem combined with etilmicin, and 63.6% (7/11) for meropenem combined with levofloxacin. There was no statistical difference between four regimens (P > 0.05). Sulbactam combined with etilmicin decreased 1/2 of MIC50 and MIC90 of sulbactam while the decreases in etilmicin were more obviously than single drug. When adopting meropenem combined with levofloxacin or etilmicin, the MIC of meropenem reduced to 1/2 of that in applying single drug. As for sulbactam or meropenem combined with levofloxacin, it also lessened the MIC50 of levofloxacin to 1/2 of that for single drug. FIC results suggested that the effects of four combined antimicrobial regimens were additive or unrelated. When sulbactam was combined with etimicin, the additive effect was 63.89%. Conclusion: Drug combination sensitivity test in vitro may be helpful for choosing antimicrobial treatment plans. Sulbactam or meropenem as the basis of treatment regimens can function as the alternatives against AB-VAP. Sulbactam combined with etimicin has been regarded as a recommended regimen in Suizhou, Hubei, China.

Keywords: Acinetobacter baumannii; combined antimicrobial therapy; in vitro drug sensitivity test; multidrug-resistant; ventilator-associated pneumonia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Drug sensitivity of Acinetobacter baumannii to 16 antibiotics in 3 years (n = 60).
Figure 2
Figure 2
Drug sensitivity of Acinetobacter baumannii to 16 antibiotics between the year of 2015 and 2017 (n = 60).
Figure 3
Figure 3
Therapeutic efficacy of four commonly used antimicrobial combinations for Acinetobacter baumannii ventilator-associated pneumonia (n = 60).
Figure 4
Figure 4
Concentration accumulated inhibition percentage curve of the antibacterial activity against multidrug-resistant Acinetobacter baumannii (n = 36).
See this image and copyright information in PMC

References

    1. Afshari A., Pagani L., Harbarth S. (2012). Year in review 2011: critical care-infection. Crit. Care 16 242–247. 10.1186/cc10425 - DOI - PMC - PubMed
    1. American Thoracic Society and Infectious Diseases Society of America (2005). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171 388–416. 10.1164/rccm.200405-644ST - DOI - PubMed
    1. Awad L. S., Abdallah D. I., Mugharbil A. M., Jisr T. H., Droubi N. S., El-Rajab N. A., et al. (2017). An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious iseases Society of America/American Thoracic Society guidelines. Infect. Drug Resist. 22 17–28. 10.2147/IDR.S145827 - DOI - PMC - PubMed
    1. Ayraud-Thévenot S., Huart C., Mimoz O., Taouqi M., Laland C., Bousseau A., et al. (2012). Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J. Hosp. Infect. 82 290–292. 10.1016/j.jhin.2012.08.016 - DOI - PubMed
    1. Bassetti M., Vena A., Castaldo N., Righi E., Peghin M. (2018). New antibiotics for ventilator-associated pneumonia. Curr. Opin. Infect. Dis. 31 177–186. 10.1097/QCO.0000000000000438 - DOI - PubMed